Arginine and proline metabolism is associated with older adult skeletal muscle mass and altered by inflammation in primary human muscle cells by Gupta, Diwakar
 i 
 
 
 
ARGININE AND PROLINE METABOLISM IS ASSOCIATED WITH OLDER 
ADULT SKELETAL MUSCLE MASS AND ALTERED BY INFLAMMATION IN 
PRIMARY HUMAN MUSCLE CELLS 
 
 
 
 
 
 
A Thesis 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Master of Science 
 
 
 
 
 
by 
Diwakar Gupta 
August 2017 
 i 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 Diwakar Gupta
 ii 
 
ABSTRACT 
 
Age-related loss of skeletal muscle mass (sarcopenia) adversely affects muscle tissue-
specific and whole-body homeostasis, suggesting an undefined relationship between 
muscle mass and whole-body circulation that underlies the etiology of sarcopenia.  
 
To investigate, 344 metabolites and analytes were measured in serum from 19 older 
adults. Arginine and proline metabolism was the pathway most closely associated with 
skeletal muscle index (SMI), a measure of skeletal muscle mass. Subsequently, gene 
expression of related transport and regulatory enzymes was measured. 
  
Younger and older adult muscle tissue had similar inflammatory signaling and gene 
expression of CAT-1 and CAT-2, the cationic amino acid transporters that allow 
arginine into muscle. However, the proinflammatory cytokine TNF-α increased CAT-2 
gene expression in differentiated human primary skeletal muscle cells. TNF-α also 
altered the expression of arginine metabolic genes regulating polyamine synthesis and 
proline production. 
 
Changes in arginine availability and metabolism may underlie the relationship 
between inflammation and skeletal muscle mass.  
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CHAPTER 1 
BACKGROUND 
Sarcopenia 
In the U.S., adults over the age of 65 are a growing demographic: they 
comprised 13.7% of the population in 2012, but this percentage will rise to 21% by 
2040 [1]. Life-expectancy at birth has increased by four years in the last two decades 
[2], but later stages of life are characterized by decreased quality of life [3]. This 
decrease in quality of life is linked to sarcopenia, the involuntary loss of skeletal 
muscle mass and associated decline in strength and function. Sarcopenia begins as 
early as the third decade of life [4] and increases the risk of frailty, injury, and 
disability in older adults [5, 6]. Low skeletal muscle mass in older adults is associated 
with difficulty performing activities of daily living (e.g., eating, bathing, climbing 
stairs, cooking, or shopping [7, 8]), suggesting that skeletal muscle mass and function 
are important for living independently and maintaining a high quality of life. 
Therapies to help maintain skeletal muscle mass with aging are essential; however, 
they are poorly defined. Development of efficacious therapies for ameliorating skeletal 
muscle deterioration with aging requires understanding the intrinsic and extrinsic 
factors that impact skeletal muscle health. 
Understanding sarcopenia is challenging because aging is a multi-factorial 
process and aging skeletal muscle differs from young muscle in a number of ways. 
Compared to younger adults, older adult skeletal muscle has impaired protein balance 
that favors atrophy. This atrophy can be attributed, in part, to blunted anabolic 
responses to hypertrophic stimuli [9] and potentially impaired regulation of protein 
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breakdown as suggested by increased gene expression of ubiquitin ligases that regulate 
protein breakdown [10]. Older adult skeletal muscle also exhibits loss of muscle fibers 
(i.e. multinucleated skeletal muscle cells) and increased atrophy of the type II 
glycolytic muscle fibers that provide rapid contractile activity [11]. The disruption of 
skeletal muscle homeostasis that occurs with aging has been attributed to factors both 
intrinsic and extrinsic to the skeletal muscle; however, the etiology and identification 
of therapeutic targets to attenuate sarcopenia remains ambiguous. 
 
Skeletal muscle—a metabolic organ system 
As the largest metabolic organ system in the human body, skeletal muscle 
metabolism affects not only skeletal muscle health, but also the health of the entire 
body. Skeletal muscle is the largest glucose sink; alterations in glucose uptake and 
metabolism by the muscle can ultimately affect glucose homeostasis throughout the 
body. Additionally, muscle releases myokines, such as interleukin 6 (IL-6), which act 
in an autocrine, paracrine, and endocrine manner [12]. Similarly, skeletal muscle is 
affected by circulating factors, such as adipokines released by adipose tissue [13]. 
Further, a parabiosis study in mice showed that serum from aged mice causes young 
mouse muscle satellite cells (i.e., muscle stem cells) to develop into fibrous connective 
tissue instead of contractile myocytes [14]. This study demonstrates that there are 
circulating factors which contribute to skeletal muscle aging, but their identity remains 
unknown. By measuring circulating factors (e.g., metabolites and analytes), it is 
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possible to study this complex network of interactions and generate testable 
hypotheses regarding the interactions between skeletal muscle and other systems. 
 
Metabolomics 
Metabolism involves complex networks of interconnected biochemical 
reactions which produce the vast assortment of metabolites needed for various 
biological functions. A change in the concentration of one metabolite can launch a 
cascade of downstream effects. Traditional metabolic studies focus on a small number 
of metabolites individually selected for measurement. Metabolomics involves the 
measurement and analysis of large quantities of metabolites to understand metabolism. 
Technologies such as nuclear magnetic resonance (NMR) and high resolution mass 
spectrometry allow researchers to measure hundreds of metabolites simultaneously. 
Traditional metabolic studies rely on selecting the correct metabolites to measure in 
order to determine some of the changes caused by a metabolic perturbation. However, 
metabolomics makes it possible to determine how a perturbation affects a metabolic 
network(s) as a whole and thus, is a useful tool for the identification of biomarkers and 
early disease states [15-17]. Metabolomics is also used for hypothesis generation: 
identifying metabolites that are associated with a particular condition or disease state, 
so that they can be studied in-depth individually [18]. Overall, metabolomics has the 
potential to allow the identification of metabolic pathways that are linked to 
sarcopenia.  
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To identify whole body metabolic disturbances that are associated with 
muscle mass and likely underlie sarcopenia, we will use serum metabolomics to 
identify circulating metabolites that are associated with SMI in older human adults.  
 
Skeletal muscle inflammation—the good and the bad 
Inflammation is a key factor in skeletal muscle regeneration and deterioration. 
Exercise is associated with an acute inflammatory response, characterized by 
increased production and secretion of cytokines such as IL-6 [19]. This acute 
inflammatory response is thought to be critical for muscle regeneration and the 
beneficial effects of exercise [20]. In contrast, chronic low-grade inflammation is 
positively associated with aging [21] and metabolic disease [22] and negatively 
associated with physical activity [23]. Chronic inflammation leads to pathological 
remodeling of the skeletal muscle (e.g. loss of myofibers and gain of fibrotic and 
adipose tissues). The proinflammatory cytokine TNF-α is a signaling molecule and an 
initiator of inflammation [24]. In older adults, circulating levels of TNF-α are 
positively associated with diminished muscle strength [25, 26] and mortality [27, 28]. 
TNF-α activates the transcription factor NF-κB, which regulates the expression of 
genes that govern skeletal muscle growth and differentiation [29]. The activation of NF-
κB is associated with multiple skeletal muscle disorders, including Duchenne 
muscular dystrophy, inflammatory myopathies, cancer cachexia, and disuse atrophy 
[30]. Although there is a known association between inflammatory signaling and 
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skeletal muscle health, the mechanisms governing this relationship are not fully 
understood.  
 
Arginine  
Arginine is a conditionally-essential amino acid that the body can synthesize 
from other metabolites. Arginine is primarily synthesized from citrulline in the kidney 
by the enzyme argininosuccinate synthase [31]. Citrulline is formed from glutamine, 
glutamate, and proline in the gut [31]. When these necessary precursors for arginine 
synthesis are absent, arginine needs to be supplied exogenously. 
Arginine supplementation may be an effective therapy to help maintain skeletal 
muscle mass. Research has demonstrated that supplements containing arginine have 
beneficial, hypertrophic effects on skeletal muscle [32-34]. Older women who 
consumed an 8.5 g mixture of arginine, β-hydroxy β-methylbutyrate (HMB), and 
lysine for 12 weeks had 20% higher whole-body protein synthesis compared to 
patients who consumed an isocaloric maltodextrin placebo, although there was no 
significant difference between groups in net protein gain [32]. The older women also 
had increased leg strength and functionality [32]. Adults with chronic inflammatory 
diseases also benefit from supplements containing arginine. Adults with HIV who 
consumed a supplement consisting of arginine, HMB, and glutamine daily for 8 weeks 
increased their lean body mass (LBM) by 2.55 kg, while subjects who received a 
maltodextrin placebo lost 0.70 kg LBM [33]. In addition, adults with cancer cachexia 
who consumed a similar supplement (as the adults in the HIV study) for 24 weeks 
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increased their fat-free mass 1.12 kg by week 4 and 1.60 kg by week 24 [34]. 
Intriguingly, healthy, young athletes do not have improved performance with 
supplemental arginine [35-38]. There is conflicting evidence to suggest arginine may 
delay fatigue during aerobic exercise in young male adults, but arginine appears to be 
acting on endothelial cells to improve blood flow during exercise, not on skeletal 
muscle cells [39]. Supplemental arginine is beneficial for muscle health in populations 
expected to have elevated inflammation, suggesting that inflammation may increase 
demand for arginine or decrease arginine synthesis.  
 
Arginine and inflammation 
The mechanism underlying the relationship between inflammation and 
arginine may involve the proinflammatory cytokine TNF-α. TNF-α is known to 
regulate arginine metabolism in rat neuronal cells, rat cardiac myocytes, and human 
vascular smooth muscle [40] by increasing gene expression of the cationic amino acid 
transporter (CAT-2). The CAT isoforms (CAT-1, CAT-2A, and CAT-2B) allow 
arginine, lysine, and ornithine to pass through the plasma membrane. TNF-α increases 
the gene expression of CAT-2 in human endothelial cells by activating the NF-κB 
signaling pathway [40], and NF-κB DNA-binding activity is increased by low arginine 
availability [41]. It is unknown if TNF-α also stimulates the gene expression of CAT-2 
in human skeletal muscle cells. We predict that TNF-α increases CAT-2 gene 
expression in human skeletal muscle cells, increasing arginine uptake. We also predict 
that increased arginine availability alters arginine metabolism, changing the relative 
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distribution of arginine metabolites and changing skeletal muscle metabolic and 
physiologic processes.  
 
Arginine and protein metabolism 
The hypertrophic effects of supplements containing arginine in adults with 
chronic inflammatory diseases suggest that one of the metabolic pathways affected by 
arginine availability is the regulation of protein balance. Supplements containing 
arginine may improve skeletal muscle mass by impacting protein balance, either by 
stimulating muscle protein synthesis (MPS), inhibiting muscle protein breakdown 
(MPB), or both. MPS is regulated by the mammalian target of rapamycin, which 
forms a complex (mTORC1) that integrates signals denoting nutritional status, energy 
status, and the presence of growth factors [42]. For example, amino acids and exercise 
are positive regulators of mTORC1 [43-46]. Although some of the factors that regulate 
MPS have been identified, the atrophic mechanisms underlying sarcopenia have not 
been fully elucidated. One contributor to sarcopenia may be a diminished hypertrophic 
response to anabolic stimuli such as essential amino acids [9]. Essential amino acids 
stimulate protein synthesis in younger adults, but older adults have a blunted response 
to this stimulus [9]. Heightened inflammation, induced by infusion of TNF-α, 
decreases MPS [47]. Additionally, animal and cell culture studies provide evidence 
that arginine alone can increase the phosphorylation of mTORC1, increase MPS, and 
increase myotube diameter [48, 49]. The interaction between arginine and mTORC1 in 
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these studies may be mediated by the lysosomal protein SLC38A9, which is necessary 
for the activation of mTORC1 by arginine [50].  
Skeletal muscle mass is also shaped by protein breakdown. Muscle protein 
breakdown (MPB) is difficult to quantify directly; therefore, regulators of protein 
breakdown such as E3 ubiquitin ligases are measured as a surrogate for MPB. 
Compared to younger adults, older adults have elevated muscle inflammatory 
signaling [51] that may disrupt MPB and thus protein balance. Compared to young 
women, older females have higher gene expression of the FoxO-regulated E3 
ubiquitin ligases MURF-1 and atrogin-1 at rest and after resistance exercise, 
respectively [10]. TNF-α increases protein expression of ubiquitin, MuRF-1, and 
atrogin-1 in rat L6 myotubes [52], and in murine C2C12 myotubes, exposure to TNF-
α increases breakdown of adult myosin heavy chain, indicative of increased protein 
catabolism [53]. Arginine ameliorates increased gene expression of MURF-1 and 
atrogin-1 in rat muscle induced by hindlimb suspension [54]. Low arginine 
availability increases the DNA-binding and activation of NF-κB [41]. Since NF-κB 
increases the gene expression of MURF-1 and atrogin-1 in addition to CAT-2 [55], 
increased arginine flux through CAT-2 may be part of a negative feedback loop that 
limits inflammatory signaling. 
Overall, these studies suggest potential pathways through which arginine may 
have protective effects against muscle protein imbalance. Arginine may activate 
mTORC1 to increase protein synthesis, ameliorate protein breakdown induced by NF-
κB or FoxO, or it may be converted into another metabolite that affects skeletal 
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muscle metabolism directly. However, it is unclear which pathways are active during 
chronic inflammation.  
 
Arginine metabolism  
Arginine may also indirectly impact skeletal muscle health by serving as a 
precursor to several different metabolites which can affect skeletal muscle 
metabolism. Arginine is required for the production of nitric oxide, a signaling 
molecule that regulates mitochondrial biogenesis [56]. Nitric oxide can bind to 
proteins in myofibrils to protect them from degradation by calpains, but aging is 
associated with reduced protein expression of neuronal nitric oxide synthase in mouse 
skeletal muscle [57]. Arginine can also be converted into polyamines, metabolites that 
regulate cell proliferation [58]. The enzyme ornithine decarboxylase 1 catalyzes the 
synthesis of the polyamine putrescine and regulates myoblast differentiation [59]. The 
polyamine spermine is a ligand for spermine oxidase, which regulates genes 
controlling muscle atrophy [60]. Arginine can also be converted to proline and 
hydroxyproline, amino acids which are abundant in collagen, a key component of 
wound healing [61]. It is not known if changes in the production of these metabolites 
are linked to inflammation or sarcopenia.  
The relationship between inflammation and arginine in skeletal muscle 
suggests that older adults with heightened inflammation may have dysfunctional 
arginine metabolism. Understanding how these alterations in arginine metabolism 
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affect skeletal muscle metabolic and physiologic processes is necessary to inform the 
development of therapies to improve skeletal muscle health in older adults.  
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CHAPTER 2 
Arginine and proline metabolism is associated with older adult skeletal muscle 
mass and altered by inflammation in primary human muscle cells 
 
Abstract 
Background: Age-related loss of skeletal muscle mass (i.e. sarcopenia) adversely 
affects muscle tissue-specific and whole-body homeostasis, suggesting an undefined 
relationship between muscle mass and whole-body circulation. Characterizing this 
relationship will further our understanding of the etiology of sarcopenia.  
Objective: Identify circulating metabolites and metabolic pathways correlated with 
skeletal muscle index (SMI), a normalized measure of skeletal muscle mass.  
Design: Serum and appendicular lean tissue measurements were collected before and 
after a 35-week resistance exercise training (RT) intervention in 19 older adults. Using 
high resolution mass spectrometry and immunoassays, 344 unique metabolites and 
analytes were analyzed from serum. MetaboAnalyst was used to identify metabolic 
pathways associated with SMI. Follow-up qPCR analysis of the most significant 
metabolic pathway was conducted on genes for transport and metabolic enzymes using 
skeletal muscle tissue and differentiated primary human skeletal muscle cell 
(myotube) cultures.  
Results: Arginine and Proline Metabolism was most strongly associated with SMI 
before and after RT. In the follow-up analysis, expression of arginine and proline 
transport and metabolism genes, cationic amino acid transporter 2, ornithine 
decarboxylase 1, pyrroline-5-carboxylate reductase 1, spermidine synthase, creatine 
17 
kinase, prolyl 4-hydroxylase subunit alpha 1, and ornithine aminotransferase were 
altered by inflammation in human myotubes.  
Conclusions: Lower levels of arginine and proline metabolites, observed among older 
adults in vivo, are consistent with reduced expression of related metabolic enzymes 
consequent to induced inflammation in vitro. These results suggest that therapies to 
manipulate arginine availability could improve skeletal muscle health in populations 
with elevated muscle inflammation, including many older adults.  
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Introduction 
The involuntary age-related loss of skeletal muscle mass (sarcopenia), as well 
as concurrent fat and fibrotic tissue accumulation within and around skeletal muscle, 
increase the risk for functional and metabolic deterioration [1]. Age-related changes in 
skeletal muscle morphology and physiology [2-4] accelerate with advancing age, and 
are accentuated by intrinsic [5-8] and extrinsic factors [9]. Factors influencing 
muscular changes have been identified in the single myofiber, the skeletal muscle 
organ system, and the whole organism. However, aging skeletal muscle is complex 
and multifactorial, and the molecular mechanisms instituting adverse changes with age 
are unclear.  
Skeletal muscle remodeling and deterioration with aging adversely affect 
muscle tissue-specific and whole-body homeostasis [10]. Conversely, whole-body 
homeostasis can adversely affect muscle mass [11], which suggests an undefined 
relationship between skeletal muscle mass and whole-body circulation. Studies using 
parabiosis [12] and primary progenitor cells [12, 13] have demonstrated that factors 
intrinsic to serum from older adults lead to impaired skeletal muscle regeneration; 
however, what circulating factors contribute to these observed age-related differences 
are ambiguous. These combined findings strongly suggest a circulating metabolic 
signature, indicative of reduced skeletal muscle mass and poor muscle health, but 
specific metabolites and analytes are largely unknown and need to be identified and 
characterized.  
Metabolomics, the comprehensive, quantitative measurement of endogenous 
metabolites from biological specimens, is a potential tool to classify samples, generate 
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hypotheses, and identify potential mechanisms and biomarkers [14-16]. Metabolomics 
has been employed to understand metabolic processes and identify biomarkers of 
chronic disease (e.g. diabetes, cancer, etc.), physiological states (e.g. cancer cachexia, 
aerobic capacity, subcutaneous and ectopic skeletal muscle fat, etc.), therapy 
responses (e.g. caloric restriction), and exercise training adaptations (e.g. strength-
endurance training). The objective of this study was to examine serum metabolites, 
using metabolomics, in older adults before and after resistance exercise training (RT) 
and identify metabolic pathways that are most closely related to skeletal muscle index 
(SMI), a widely used indicator of sarcopenia [17]. Follow-up analyses were aimed at 
interrogating identified metabolic pathways associated with SMI to further our 
understanding of potential mechanisms driving muscle atrophy with aging. 
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Materials and Methods  
Subjects 
The metabolomics study was conducted as a secondary analysis of a subset of 
collected serum samples, dietary records, and body composition data (see Figure 1 for 
study design) on 19 older men (n = 6) and women (n = 13) aged 60 - 75 y (Table 1). 
For the parent resistance exercise training (RT) study, all subjects were recruited from 
the greater Birmingham, Alabama area. A health history and physical activity 
questionnaire as well as a comprehensive physical exam were completed by all 
subjects during screening. Subjects also passed a diagnostic, graded exercise stress test 
with 12-lead electrocardiogram reviewed by a cardiologist. Subjects were excluded 
from the study if they reported any musculoskeletal or other disorders that would have 
affected their ability to complete exercise training and testing for the study; were 
obese (BMI > 30.0 kg/m
2
); performed knee extensor RT within the past 5 y; or were 
treated with exogenous testosterone or other pharmacological interventions known to 
influence muscle mass or muscle recovery.  
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Figure 1: Experimental design of parent metabolomics study (conducted at UAB) and follow-up study (conducted at Cornell). 
DXA, dual x-ray absorptiometry; FACS, fluorescence activated cell sorting; HPLC-MS, high-performance liquid chromatography 
mass spectrometry; RT, resistance exercise training; UAB, University of Alabama at Birmingham 
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Table 1. Subject characteristics for resistance exercise training (RT) intervention 
 Baseline RT 
Subjects (females) 19 (13) 19 (13) 
# Sarcopenic 2 1 
Age, y
 
65 ± 1       66 ± 1*** 
Weight, kg 77.7 ± 2.9 78.1 ± 2.9 
BMI 26.1 ± 0.7 26.3 ± 0.7 
ApLM, kg 21.1 ± 1.1     21.6 ± 1.1** 
SMI, kg/m
2
   7.0 ± 0.3       7.2 ± 0.3** 
Lean body mass, kg 46.3 ± 2.0       47.4 ± 1.9*** 
Fat mass, kg 28.0 ± 1.7 27.5 ± 1.6 
Means ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001, significantly different from 
baseline (paired t-test). ApLM, appendicular lean mass; RT, resistance exercise 
training; SMI, skeletal muscle index (ApLM divided by height squared).  
 
Follow-up experiments to the metabolomics analysis (see Figure 1 for study 
design) involved collection of both skeletal muscle tissue and/or human primary 
satellite cells from 11 younger men (n = 6) and women (n = 5) aged 21 - 39 y and 10 
older men (n = 4) and women (n = 6) aged 68 - 80 y who were recruited from the 
Tompkins County, New York area. Individuals in the follow-up study completed a 
comprehensive health history and physical activity questionnaire that was reviewed by 
a nurse practitioner. Individuals were excluded for any chronic end-stage disease 
expected to limit life-expectancy to less than one year, induce anorexia, or restrict 
physical activity; if they had a seated resting systolic blood pressure > 140 mm Hg or 
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diastolic blood pressure > 90 mm Hg; or if they were currently adhering to a weight-
reduction diet. 
Studies were approved by the Institutional Review Boards of the University of 
Alabama at Birmingham (UAB) and Cornell University, respectively. All subjects 
provided written informed consent prior to participation.  
 
METABOLOMICS STUDY 
Resistance training and dietary analysis 
All subjects underwent 35 weeks of supervised, whole-body, progressive RT. 
Subjects were randomly assigned into one of four RT programs [high-resistance 
concentric-eccentric training (H) 3 d/wk (HHH); H training 2 d/wk (HH); 3 d/wk 
mixed model training consisting of  H training 2 d/wk separated by one bout of low-
resistance, high-velocity, concentric only (L) training (HLH); or 2 d/wk mixed model 
consisting of H training 1 d/wk and L training 1 d/wk (HL)]. All subjects were asked 
to maintain their habitual diet throughout the RT study. Four-day diet records were 
collected at the beginning and end of the 35-wk RT to monitor habitual intake. Diet 
records were analyzed using Nutrition Data System for Research 2013 (University of 
Minnesota), a dietary analysis program. Diet record data were used to determine 
whether dietary macronutrient or micronutrient intake affected SMI or circulating 
metabolite concentrations. In addition to their habitual diet, subjects consumed 0.3 g 
per kg body weight of 80% whey protein concentrate (WPC80, Agri-Mark, Methuen, 
Massachusetts) immediately before and after each exercise session throughout the 35-
wk RT. All subjects consumed a total of 0.6 g of WPC80 per kg body weight every 
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Monday, Wednesday, and Friday throughout the 35-wk study, including participants 
assigned to RT 2 d/wk.   
 
Anthropometrics and body composition 
Prior to and after the 35-wk RT, a stadiometer was used to measure height, and 
a dual x-ray absorptiometry (DXA) scan was used to measure fat, lean (total and 
appendicular), and bone masses. SMI was calculated as appendicular lean mass (kg) / 
height
2 
(m
2
).  
  
Serum metabolomics and analyte measurements 
Serum collected from participants in each of the four RT training programs 
[HHH (n = 4), HH (n = 5), HLH (n = 5), HL (n=5)] was analyzed for metabolite 
concentrations. Before and after the 35-wk intervention, subjects were asked to 
complete an overnight fast and report to the metabolic unit at UAB. Serum was 
collected via venipuncture by a trained nurse. Serum was aliquotted and stored at  
-80°C. For polar metabolite extraction, 25 µL of serum were extracted with 500 µL of 
80% methanol (HPLC grade) chilled over liquid nitrogen vapor and centrifuged [18]. 
Supernatants containing the polar solvents were dried and concentrated using a 
vacuum concentrator (SpeedVac Concentrator, Savant) [18]. Concentrated samples 
were reconstituted in water and acetonitrile, then analyzed using high-resolution mass 
spectrometry coupled to liquid chromatography (HPLC-MS) to measure 338 
metabolites [19]. Immunoassay was used to measure seven analytes: glucose, TNF-α, 
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IL-6, IL-1β, IL-10, leptin, and insulin using the Dimension Xpand (Siemens) and the 
Magpix (Luminex), following manufacturer protocols. 
 
Statistical analysis—metabolomics study 
Statistical analysis was performed using the R software environment (R Core 
Team, Vienna, Austria), except where noted. A paired t-test was used to identify 
subject characteristics, circulating metabolites, and dietary components that changed 
during the intervention. The association between SMI and a circulating metabolite or a 
dietary nutrient was calculated using Pearson’s correlation, r. The false discovery rate 
(FDR) was controlled using the Benjamini-Hochberg procedure to adjust for multiple 
comparisons, and adjusted p-values < 0.05 were considered significant [20, 21]. 
The Pathway Analysis function of MetaboAnalyst 3.0 was used to identify 
biochemical pathways that were associated with SMI [22, 23]. If a metabolite had 
multiple isomers that could not be distinguished by mass spectrometry, the 
concentrations for that metabolite were inputted multiple times, labeled as each 
different isomer. MetaboAnalyst recognized 330 compounds, including multiple 
isomers, from the dataset. Interquartile range filtering removed the 5% of compounds 
that showed the lowest variation with SMI. No sample normalization, data 
transformation, or data scaling was applied. The Homo Sapiens pathway library was 
used by MetaboAnalyst for analysis. Pathway topology analysis determined the 
importance of each measured metabolite in a biochemical pathway by counting the 
number of shortest paths that passed through each metabolite (relative betweenness 
centrality). Then the importance of the measured metabolites was normalized by the 
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total importance of all the metabolites in the pathway to determine the pathway impact 
of each measured metabolite. 
 
FOLLOW-UP STUDY 
Muscle biopsies 
Skeletal muscle biopsies were performed by a nurse practitioner in the Human 
Metabolic Research Unit (HMRU) at Cornell University. After an overnight fast, 
subjects reported to the HMRU, vitals were measured, and subjects rested in the 
supine position. A percutaneous needle biopsy of the vastus lateralis was taken using a 
5.0 mm Bergstrom biopsy needle with suction under local anesthetic (1% lidocaine). 
Tissue was quickly blotted with sterile gauze, and visible adipose and connective 
tissues were removed. Skeletal muscle aliquots were either snap frozen in liquid 
nitrogen and stored at -80°C or were placed in Gibco® Hibernate®A (Thermo Fisher 
Scientific, Waltham, Massachusetts) for harvesting primary satellite cells. 
 
Primary human myoblast purification and cell culture  
To harvest primary satellite cells, a 70-100 mg portion of biopsy tissue was 
cleaned of extraneous fascia and adipose tissue and washed via gravity with 
Dulbecco’s PBS. Tissue was dissociated via incubation at 37°C in DMEM (Gibco, 
Thermo Fisher, Waltham, Massachusetts) containing 10 mM HEPES, 0.03% EDTA, 
0.12% Pronase E with periodic titurating until a homogeneous suspension was 
achieved. The cell suspension was then passed through a 70 µm cell strainer into an 
equal volume of FBS (GE Healthcare Hyclone, Little Chalfont, United Kingdom), and 
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centrifuged at room temperature for 5 minutes at 300 rcf. The resulting pellet was 
resuspended in myoblast growth medium [(GM) Ham’s F12 (Gibco, Thermo Fisher, 
Waltham, Massachusetts) supplemented with 20% FBS, 1% penicillin/streptomycin 
(Gibco, Thermo Fisher, Waltham, Massachusetts), and 5 ng/mL recombinant human 
basic fibroblast growth factor (Promega, Madison, Wisconsin)]. Cells were depleted of 
fibroblasts by preplating followed by culture on Type I-collagen (Corning, Corning, 
New York) coated culture dishes at an initial cell confluency of ~15%. After 24 hours, 
media was replaced with fresh GM and then further replenished every 48 hours. When 
cultures reached 75-80% confluence, cells were detached from the plate using 0.05% 
Trypsin-EDTA (Gibco, Thermo Fisher, Waltham, Massachusetts). Cultures were 
expanded through passage three followed by cryopreservation in 10% DMSO + GM.   
Although no testing for mycoplasma contamination was performed, pure 
populations of primary myoblasts were obtained by rapidly thawing approximately 1-
1.5 million passage four cells and labeling with fluorescently conjugated antibodies to 
cell surface antigens CD56 (NCAM; PE-Cy7 Mouse anti Human CD56 (Clone B159),  
BD Pharmigen, San Jose, California) and CD29 (integrin β1; Alexa Fluor 488 anti-
human CD29, Biolegend, San Diego, California) and the viability stain 7-
Aminoactinomycin D (7-AAD, eBioscience, San Diego, California) [24]. Live 
CD56+/29+ cells were collected via fluorescence activated cell sorting (FACS) using 
a BD FACS Aria Fusion flow cytometer (Biotechnology Resource Center, Cornell 
University) and subcultured once before cryopreservation.   
Freshly thawed, passage 6, CD56+/CD29+ cells from young males (n = 6) and 
young females (n = 5) were seeded at a density of approximately 15%, cultured in GM 
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until ~80% confluent, rinsed with Ham’s F12 media to remove any residual serum or 
growth factors, and switched to differentiation media [(DM) Ham's F12 supplemented 
with 2% heat inactivated equine serum (Gibco, Thermo Fisher, Waltham, 
Massachusetts), 1% penicillin/streptomycin]. DM was replenished every 24 hours. 
After 72 hours, cells were then incubated for an additional 48 h in DM with or without 
10 ng/mL of TNF-α (recombinant human TNF-α, Merck Millipore, Darmstadt, 
Germany) before cells were harvested. 
 
RNA isolation from tissue homogenates and primary cell culture 
RNA was obtained from snap frozen skeletal muscle tissue (20-30 mg) via 
pulverization using a liquid nitrogen-cooled Bessman tissue pulverizer followed by 
homogenization in TRIzol (Life Technologies, Carlsbad, California) with a rotor-
stator homogenizer, following the manufacturer’s protocol with the following 
modifications. Phase separation was achieved with 1-bromo, 3-chloropropane (120 µL 
per 1 mL TRIzol) followed by a 10 minute incubation at room temperature and 
centrifugation at 13,000 g for 15 minutes in a 4°C centrifuge. Following the addition 
of isopropanol and incubation at room temperature for 10 minutes, lysates were 
centrifuged at 12,600 g for 15 minutes in a 4°C centrifuge. The resulting RNA pellet 
was washed 3 times in 75% ethanol, each followed by centrifugation at 4°C and 
10,000 g for 5 minutes. 
For cultured cells, RNA was extracted and purified using the E.Z.N.A Total 
RNA Kit (Omega Biotek, Norcross, Georgia) including an on-Column DNAse digest 
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(Qiagen, Hilden, Germany). Total RNA quantity and quality was assessed using a 
Spectramax M3 spectrophotometer (Molecular Devices). 
 
Quantitative polymerase chain reaction (qPCR) 
 qPCR was performed using TaqMan Gene Expression Assays (Thermo Fisher 
Scientific, Waltham, Massachusetts) for selected genes. cDNA was reverse transcribed 
from both skeletal muscle and cultured cell RNA using High Capacity Reverse 
Transcriptase (Applied Biosystems, Foster City, California). The relative gene 
expressions of TNF-α (Hs01113624_g1), TNF receptor 1 (TNF-R1, Hs00533560_m1), 
nuclear factor kappa B subunit 1 (NFKB1, HS00765730_m1), signal transducer and 
activator of transcription (STAT3, Hs00374280_m1), IL-6 (Hs00985639_m1), IL-6 
receptor (Hs00794121_m1), IL-6 signal transducer (GP130, Hs00174360_m1), and 
the cationic amino acid transporters (CAT-1, Hs00931450_m1, and CAT-2, 
Hs00952727_m1) were measured with TaqMan Fast Advanced Master Mix (Applied 
Biosystems, Foster City, California) on a LightCycler 480 (Roche) running the 
following cycling program: 50°C, 2 min; 95°C, 5 min; 40 cycles of 95°C, 10 sec and 
60°C, 30 sec. Gene expression was normalized using human ribosomal RNA 18s 
(Hs99999901_s1) or TATA-box binding protein (TBP, Hs00427621_m1) as an 
endogenous control.  
  
PrimePCR Panel 
RNA from cultured cells from young females (n = 5) was used to measure the 
expression of genes that regulate arginine metabolism (Table 2). The iScript advanced  
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Table 2. Genes that were measured for expression using the PrimePCR Panel  
Symbol Gene  
AGMAT agmatinase 
ALDH18A1 pyrroline-5-carboxylate synthase 
ALDH4A1 pyrroline-5-carboxylate dehydrogenase 
ARG2 arginase 2 
ASL argininosuccinate lyase 
ASS1 argininosuccinate synthase 
B2M beta-2-microglobulin 
CKM creatine kinase, muscle 
GLS glutaminase 
NOS2 nitric oxide synthase 2 
OAT ornithine aminotransferase 
ODC1 ornithine decarboxylase 1 
OTC ornithine carbamoyltransferase 
P4HA1 prolyl 4-hydroxylase subunit alpha 1 
PPIA peptidylprolyl isomerase A 
PYCR1 pyrroline-5-carboxylate reductase 1 
RPLP0 ribosomal protein lateral stalk subunit P0 
SMOX spermine oxidase 
SRM spermidine synthase 
 
cDNA synthesis kit (Bio-Rad, Hercules, California) was used to synthesize cDNA 
from 0.32 μg of RNA. The reaction was incubated at 42°C for 30 min and then heated 
to 85°C for 5 min to inactivate the reverse transcriptase. To perform qPCR, cDNA was 
added to the 2x SsoAdvanced Universal SYBR Green Supermix (Bio-Rad, Hercules, 
California) along with RNase-free water to create the qPCR mixture. To load 10 ng of 
cDNA to each well, 20 µL of the qPCR mixture were added to each well of the custom 
PrimePCR Panel. The plate was sealed and centrifuged to remove bubbles. The 
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LightCycler 480 (Roche) ran the following cycling program: 95°C, 2 min; 40 cycles of 
95°C, 5 sec and 60°C, 30 sec, with a ramp rate of 4.4°C/s. After completing the run, 
dissociation curve analysis was performed by increasing the temperature from 60°C to 
95°C by 4.4°C/sec. The presence of a single peak in each reaction at temperatures 
greater than 80°C was used to verify qPCR specificity. 
The NormFinder program was used to select housekeepers for normalizing 
gene expression measured with the PCR panel [25]. Gene expression was normalized 
using the geometric mean of beta-2-microglobulin (B2M) and ribosomal protein lateral 
stalk subunit P0 (RPLP0) as endogenous controls.  
 
Statistical analysis—follow-up study 
A two-factor ANOVA was computed in Prism 4 (GraphPad, La Jolla, 
California) to determine the effects of age and sex on gene expression in skeletal 
muscle tissue. A paired t-test was computed in Excel 2013 (Microsoft, Redmond, 
Washington) to determine the effect of TNF-α on in vitro gene expression measured 
with Taqman Gene Expression Assays or the PrimePCR panel. The ΔΔ Cp method 
was used to calculate fold change of gene expression [26]. For all measurements of 
gene expression, the FDR was controlled using the Benjamini-Hochberg procedure to 
adjust for multiple comparisons [20, 21]. Results were considered statistically 
significant if p < 0.05.  
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Results 
Baseline and 35-wk RT characteristics of the subjects in the metabolomics 
study can be seen in Table 1. After 35 weeks of RT, a paired t-test demonstrated 
subjects increased appendicular lean mass (0.5 kg); consequently, there was a 
significant increase in SMI after RT (0.2 kg/m
2
, Table 1). No changes in habitual 
intake of energy, carbohydrates, fat, vitamins, or minerals were found throughout RT. 
When the nutrients from the WPC80 shakes were excluded from the dietary analysis, 
there were no significant changes in total protein intake or individual amino acid 
intake. Therefore, we conclude that subjects maintained their habitual diet throughout 
the RT intervention. By calculating Pearson’s correlation, we observed that SMI was 
not associated with dietary intake at baseline or after RT (Table 3). 
 
Table 3. Association between skeletal muscle index (SMI) and dietary intake in older 
adults at baseline and after resistance exercise training (RT) 
1
 
 Baseline RT 
 r 
2
p-value r 
2
p-value 
Total energy 0.27 0.99 0.40 0.71 
Total protein 0.14 0.99 0.22 0.71 
Total carbohydrate 0.36 0.99 -0.10 0.81 
Total fat 0.17 0.99 0.55 0.71 
1 The Pearson’s correlation, r, between dietary intake and SMI was calculated at 
baseline and after RT. n = 19 older adults. 
2
 P-value after adjusting for multiple comparisons using the false discovery rate.
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Metabolic pathways significantly associated with skeletal muscle index (SMI) 
Using pathway topology analysis, MetaboAnalyst identified metabolic 
pathways that were associated with SMI at baseline and pathways associated with SMI 
after RT. The most impactful SMI-associated pathways were the same at baseline and 
after RT. Therefore, we grouped metabolite measurements from baseline and RT 
together and searched for pathways that were associated with SMI. MetaboAnalyst 
identified fifteen pathways that contained metabolites that were strongly associated 
with SMI (Figure 2, Table 4). Two of these pathways, Valine, leucine, and isoleucine 
biosynthesis and Phenylalanine, tyrosine and tryptophan biosynthesis, do not occur in 
humans and therefore, they are not relevant in this biological context. Arginine and 
proline metabolism was identified as the metabolic pathway that was most strongly 
associated with SMI, with a high impact and a high number of matches (Figure 2). The 
Arginine and proline metabolism pathway contains 77 metabolites, of which 20 were 
measured in the serum samples. MetaboAnalyst also calculated the Pearson’s 
correlation between SMI and each individual metabolite, and seven of the 20 
measured metabolites in the Arginine and proline metabolism pathway were 
individually associated with SMI (p < 0.05, FDR-corrected, Figure 3). Six of these 
seven metabolites (i.e., creatinine, glutamate, 1-pyrroline-2-carboxylate, proline, 
pyrroline-5-carboxylate, and l-4-hydroxy-glutamate semialdehyde) were positively 
associated with SMI and one metabolite (i.e., creatine) was negatively associated with 
SMI. 
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Figure 2: Impact and number of matches for each metabolic pathway associated with 
skeletal muscle index (SMI). The Pathway Analysis function of MetaboAnalyst was 
used to determine which biochemical pathways contained metabolites whose 
concentrations were associated with skeletal muscle index. Matches represent the 
number of metabolites in each pathway that were individually associated with SMI (p 
> 0.05, FDR-corrected). Impact represents how important the measured metabolites 
are to the entire pathway and is calculated using the relative betweenness centrality. 
Arginine and proline metabolism was the metabolic pathway with the highest 
combined matches and impact. SMI, skeletal muscle index. 
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Table 4. Metabolic pathways identified by MetaboAnalyst to contain serum 
metabolites associated with skeletal muscle index (SMI) 
1
 
Pathway 
2
Total 
Compounds 
3
Hits 
4
Matches  
5
Impact 
Arginine and proline metabolism 77 20 7 0.52 
Valine, leucine and isoleucine 
degradation 
40 7 2 0.08 
Valine, leucine and isoleucine 
biosynthesis 
27 7 2 0.18 
Aminoacyl-tRNA biosynthesis 75 19 7 0.23 
Pyrimidine metabolism 60 14 2 0.27 
Tryptophan metabolism 79 9 1 0.28 
Phenylalanine, tyrosine and 
tryptophan biosynthesis 
27 4 2 0.08 
Porphyrin and chlorophyll 
metabolism 
104 4 1 0.01 
Linoleic acid metabolism 15 5 1 0.89 
Riboflavin metabolism 21 2 1 0.15 
Glutathione metabolism 38 7 1 0.08 
Nitrogen metabolism 39 12 3 0.01 
Butanoate metabolism 40 6 1 0.16 
Sulfur metabolism 18 3 0 0.29 
Sphingolipid metabolism 25 1 0 0.00 
1
 Analysis was conducted using both baseline and RT measurements. n = 19 older 
adults. RT, resistance exercise training; SMI, skeletal muscle index. 
2
 Total compounds, the number of compounds in the pathway  
3
 Hits, the number of compounds in the pathway that were measured in serum 
4
 Matches, the number of compounds in the pathway that were individually associated 
with SMI (p > 0.05) 
5
 Impact, the importance of the hits in the pathway, based on the number of hits and 
their centrality in the metabolic network  
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Figure 3: Arginine and proline metabolism was identified by MetaboAnalyst as the 
biochemical pathway most closely associated with skeletal muscle index (SMI) in the 
serum metabolites of 19 older adults (global test, p = 0.0003, FDR-corrected). 
MetaboAnalyst calculated the correlation of each individual metabolite with SMI 
(Pearson’s r, p < 0.05, FDR-corrected). Compounds were positively associated (green 
box), negatively associated (red box), or not associated (white box) with SMI, or not 
measured (gray box) in our dataset. Further, inflammation induced by TNF-α, in our 
in vitro model, decreased (green print), increased (red print), or did not affect (black 
print) the gene expression of key arginine and proline metabolic enzymes that were 
measured (fold change below the corresponding enzyme). Paired t-tests were used to 
identify significant differences between treated and control cells (p < 0.05, FDR-
corrected). AGMAT, agmatinase; ALDH4A1, pyrroline-5-carboxylate dehydrogenase; 
ALDH18A1, pyrroline-5-carboxylate synthase; ARG2, arginase 2; ASL, 
argininosuccinate lyase; ASS1, argininosuccinate synthase; CKM, creatine kinase, 
muscle; GLS, glutaminase; FDR, false discovery rate; NOS2, nitric oxide synthase 2 
(inducible); OAT, ornithine aminotransferase; ODC1, ornithine decarboxylase 1; OTC, 
ornithine carbamoyltransferase; PYCR1, pyrroline-5-carboxylate reductase 1; P4HA1, 
prolyl 4-hydroxylase subunit alpha 1; SMI, skeletal muscle index; SMOX, spermine 
oxidase; SRM, spermidine synthase. 
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Arginine metabolism and skeletal muscle 
To better understand the relationship between skeletal muscle health and 
arginine and proline metabolism, we measured the gene expression of the arginine 
transporters, cationic amino acid transporters 1 and 2 (CAT-1 and CAT-2, 
respectively), in younger (21-39 y, n = 6 males and 5 females) and older (68-80 y, n = 
4 males and 6 females) adult skeletal muscle biopsies collected in the follow-up 
experiment. A two-factor ANOVA showed that there were no age- or sex-related 
differences in the gene expression of CAT-1 and CAT-2 in the skeletal muscle tissue of 
the younger and older adults after the FDR correction (Figure 4). 
Other studies have previously reported a link between CAT-2 gene expression 
and inflammation in endothelial cells [27, 28]. Additionally, we have previously 
observed elevated markers of skeletal muscle inflammation in older adults [29], as 
well as clear evidence of heightened skeletal muscle inflammation susceptibility 
(MuIS) with advancing age that manifests both in muscle tissue and in isolated 
myogenic cells in vitro [30]. Therefore, we determined whether these older (vs. 
younger) adults had heightened MuIS. In a subset of subjects, a two-factor ANOVA 
on age and sex demonstrated that there were no differences between younger and older 
subjects in the gene expression of the inflammatory markers TNF-α, STAT3, NFKB1, 
IL-6 (Figure 4), or the IL-6 receptors (IL-6R and GP130). 
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Figure 4: Gene expression of inflammatory signals (A) IL-6 and (B) NFKB1, and the 
arginine transporters (C) CAT-1 and (D) CAT-2 in human skeletal muscle tissue from 
young (n = 11) and old (n = 10) adults. Means ± SEM. A two-factor ANOVA was 
used to identify significant effects of age and sex (p < 0.05, FDR-corrected). Values 
were normalized to TBP gene expression. All values are expressed relative to gene 
expression in young males. CAT, cationic amino acid transporter; FDR, false 
discovery rate, NFKB1, nuclear factor kappa B; TBP, TATA-box binding protein. 
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Although we were likely underpowered, after adjusting for the FDR, to 
observe differences in MuIS in our follow-up cohort, the older adults did not appear to 
have heightened MuIS, based on a targeted gene expression profile. Therefore, we 
used a primary cell culture model to further investigate the effects of inflammation on 
arginine transport in differentiated primary human myoblasts/myotubes. Cells from 
young adults were used for these experiments to isolate the effects of inflammation 
from other age-related effects. Paired t-tests showed that treating differentiated 
primary myoblasts/myotubes from young male (n = 6) and young female (n = 5) adults 
with TNF-α induced a 32-fold increase in the gene expression of IL-6 in males (p < 
0.001, FDR-corrected) and a 16-fold increase in females (p < 0.001, FDR-corrected, 
Figure 5). TNF-α also induced a 3.1-fold increase in the gene expression of NFKB1 in 
males (p < 0.001, FDR-corrected, Figure 5) and a 4.3-fold increase in females (p < 
0.001, FDR-corrected, Figure 5). Although CAT-1 gene expression changed in male 
myoblasts/myotubes incubated in TNF-α (p = 0.045, FDR-corrected), the -1.1 fold-
change was not biologically meaningful. There was no change in CAT-1 gene 
expression in female cultures treated with TNF-α. However, the expression of CAT-2 
increased 11-fold in males (p = 0.0023, FDR-corrected) and 23-fold in females (p = 
0.001, FDR-corrected) following 48 hour TNF-α treatment (Figure 5). 
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Figure 5: Gene expression of IL-6, NFKB1, and arginine transporters CAT-1 and 
CAT-2 in human primary skeletal muscle cells that were incubated in TNF-α to induce 
inflammation. Means ± SEM. Values were normalized to TBP gene expression 
(females, n=5) or 18S gene expression (males, n=6) and are expressed relative to 
same-sex controls. *, p < 0.05; **, p < 0.01; ***, p < 0.001, significantly different 
from untreated controls (paired t-test) after FDR-correction. NFKB1, nuclear factor 
kappa B subunit 1; TBP, TATA-box binding protein. 
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The magnitude of the CAT-2 response in the female cells treated with TNF-α 
led us to test the effects of inflammation on the expression of key metabolic genes 
important for arginine and proline metabolism in the female cells. Of the sixteen genes 
analyzed, inflammation induced a decrease in the expression of five genes (ornithine 
decarboxylase 1, pyrroline-5-carboxylate reductase 1, spermidine synthase, creatine 
kinase, and ornithine aminotransferase) and an increase in the expression of one gene 
(prolyl-4-hydroxylase subunit alpha 1) (Table 5, Figure 3). 
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Table 5. Changes in the gene expression of arginine metabolic enzymes induced by 
TNF-α in vitro in human primary skeletal muscle cells 
Gene Symbol Gene Name p-value 
†
  Fold-change 
ODC1 ornithine decarboxylase 1 0.0010* -2.21 
PYCR1 pyrroline-5-carboxylate reductase 1 0.0016* -2.62 
SRM spermidine synthase 0.0096* -1.66 
CKM creatine kinase, muscle 0.0108* -2.55 
P4HA1 prolyl 4-hydroxylase subunit alpha 1 0.0165* 1.63 
OAT ornithine aminotransferase 0.0200* -1.39 
GLS glutaminase 0.0609 -1.34 
ALDH18A1 pyrroline-5-carboxylate synthase 0.0609 -1.28 
ASS1 argininosuccinate synthase 0.0774 -1.49 
NOS2 nitric oxide synthase 2 (inducible) 0.0797 -1.53 
OTC ornithine carbamoyltransferase 0.0797 -1.53 
ALDH4A1 pyrroline-5-carboxylate dehydrogenase 0.2049 -1.37 
SMOX spermine oxidase 0.2783 -1.31 
ARG2 arginase 2 0.4853 1.04 
ASL argininosuccinate lyase 0.7134 -1.06 
AGMAT agmatinase 0.7134 -1.06 
 
Cultured human primary skeletal muscle cells from young adult females were 
incubated in TNF-α to induce inflammation. qPCR was used to measure changes in 
the gene expression of enzymes governing arginine metabolism. n = cells from 5 
young females grown in triplicate in vitro.  
† P-value after adjusting for multiple comparisons using the false discovery rate. *, p < 
0.05, significantly different from paired control (paired t-test). 
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Discussion 
This study is the first to identify an association between Arginine and proline 
metabolism and a marker of skeletal muscle health, SMI, in older adults. While other 
key amino acid metabolism pathways (e.g., Valine, leucine, and isoleucine 
degradation) were also associated with SMI, Arginine and proline metabolism was the 
most strongly associated pathway with the largest impact. Although possible, it is 
unlikely that the observed association is attributed to consumption of arginine- and 
proline-rich foods, because the serum used for the metabolite analysis was collected 
after an overnight fast, and habitual dietary intake of arginine, proline, or a substrate 
used for the synthesis of these amino acids was not associated with SMI at baseline or 
after RT (data not shown). Based on our follow-up analyses, we can speculate whether 
the observed association between arginine and proline metabolism and SMI is due to 
low-grade inflammation and heightened MuIS observed with skeletal muscle atrophy 
in older adults.  
Arginine is a conditionally-essential amino acid that is synthesized from other 
metabolites in the body. The majority of endogenous arginine synthesis in human 
adults occurs when citrulline travels from the small intestine to the kidney, where it is 
converted into arginine by argininosuccinate synthase [31]. Glutamine, glutamate, and 
proline serve as precursors for citrulline [31]. Healthy adults have the capacity to 
synthesize sufficient arginine to satisfy metabolic requirements [32]. In the current 
study, subjects with lower SMI also displayed diminished circulating glutamate and 
proline, potentially indicating an insufficient precursor supply for citrulline production 
and thus insufficient intestinal-renal arginine synthesis in older adults with lower 
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muscle mass. It is possible that alterations in arginine metabolism and availability 
affect SMI by altering muscle protein synthesis. Arginine activates the mechanistic 
target of rapamycin (mTOR) signaling pathway, increasing phosphorylation of the 
eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and the 
fractional rate of skeletal muscle protein synthesis [33]. Future research is necessary to 
determine whether the relationship between arginine metabolism and SMI is linked to 
mTOR activity. 
Studies demonstrate that supplements containing arginine are beneficial for 
maintaining skeletal muscle mass or performance in aging or chronically ill 
individuals who likely have elevated inflammation [34-36]. Older women who 
received an 8.5 g mixture of arginine, β-hydroxy β-methylbutyrate (HMB), and lysine 
for 12 weeks had 20% higher whole-body protein synthesis compared to patients who 
consumed an isocaloric maltodextrin placebo, although there was no significant 
difference between groups in net protein gain [35]. The older women also had 
increased leg strength and functionality [35]. Additionally, adults with HIV who 
consumed a supplement consisting of arginine, HMB, and glutamine daily for eight 
weeks increased their lean body mass (LBM), while subjects who received a 
maltodextrin placebo lost LBM [34]. Adults with cancer cachexia who consumed a 
similar supplement (as the adults in the HIV study) for 24 weeks increased their fat-
free mass over 24 weeks [36]. Despite the positive effects of arginine on skeletal 
muscle in older women and chronically ill patients, arginine supplementation did not 
improve performance in healthy athletes [37-40]. These differential responses to 
supplements containing arginine, among various populations, suggest alterations in 
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arginine synthesis and/or metabolism that would make arginine an essential amino 
acid in some populations, including older adults with declining skeletal muscle mass. 
Supplements containing arginine were beneficial to populations that have 
elevated inflammation [41], which is a key factor in skeletal muscle regeneration and 
deterioration. The acute inflammation that occurs after exercise is vital for muscle 
regeneration and thought to be responsible for the beneficial effects of exercise on 
whole-body health [42]. In contrast, chronic low-grade inflammation is associated 
with aging [43] and metabolic disease [44], negatively associated with physical 
activity [45], and causes skeletal muscle to lose myofibers and gain fibrotic and 
adipose tissues. Circulating levels of the proinflammatory cytokine TNF-α, a signaling 
molecule and initiator of inflammation [46], are positively associated with diminished 
muscle strength [47, 48] and mortality [49, 50] in older adults. TNF-α activates the 
transcription factor NF-κB, which is associated with multiple skeletal muscle 
disorders, including Duchenne muscular dystrophy, inflammatory myopathies, cancer 
cachexia, and disuse atrophy [51].  
Given the association between older adults, inflammation, and sarcopenia, we 
sought to determine whether the relationship between skeletal muscle and arginine 
metabolism involved inflammation, specifically TNF-α. TNF-α regulates arginine 
metabolism in rat neuronal cells, rat cardiac myocytes, and human vascular smooth 
muscle [28] by increasing gene expression of the cationic amino acid transporter 
(CAT-2). The CAT isoforms (CAT-1, CAT-2A, and CAT-2B) allow arginine, lysine, 
and ornithine to pass through the plasma membrane. TNF-α increases the gene 
expression of CAT-2 in human endothelial cells by activating the NF-κB signaling 
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pathway [28], and NF-κB DNA-binding activity is increased by low arginine 
availability [52]. We predicted older adults would have an elevated proinflammatory 
gene expression profile and elevated arginine transporter expression compared to 
younger adults. Surprisingly, young and old subjects had similar levels of 
inflammatory and CAT-1 and CAT-2 gene expression, potentially due to the relatively 
active, healthy older adults in the follow-up study. It is also possible that we were 
underpowered, after adjusting for the FDR, to measure differences in the gene 
expression of the arginine transporters. We also predicted that TNF-α increases CAT-2 
gene expression in human skeletal muscle cells, increasing arginine uptake. We 
observed a robust increase in CAT-2 gene expression in primary myoblast/myotube 
cultures from males and females following incubation with TNF-α, a response that has 
been previously reported in other cell lines [27, 28], but not in skeletal muscle cells. 
Although we do not know if arginine uptake was altered, the increased expression of 
this arginine transporter may be a signal of increased demand for arginine in an 
inflamed state. Intriguingly, it has been demonstrated that arginine is important for 
attenuating NF-κB activity in keratinocytes [52]. We demonstrated that NFKB1 
expression is elevated in our culture model, further supporting a potential role of 
arginine during heightened inflammation. 
Forty-eight hours of inflammation affected key metabolic pathways for 
arginine and proline metabolism, including decreased polyamine production and 
proline synthesis. The timing and duration of this inflammation may have been critical 
to the observed effects. Decreased expression of ODC1 and SRM with TNF-α 
treatment could be an indication of disrupted skeletal muscle regenerative and/or 
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atrophic mechanisms through disruption of polyamine synthesis. Polyamines such as 
putrescine and spermidine are important for the regulation of cell proliferation and 
delay of myoblast differentiation [53]. Spermine oxidase (SMOX) converts the 
polyamine spermine into spermidine and regulates genes that control muscle atrophy 
[54]. Inflammation also altered the expression of proline and hydroxyproline synthesis 
genes (OAT, PYCR1, and P4HA1). Proline and hydroxyproline comprise 25% of the 
amino acid residues of collagen, which is critical for wound healing [55]. Lastly, CKM 
gene expression was reduced with inflammation, an indication that myoblast fusion is 
disrupted in our model [56]. Lower gene expression of key metabolic enzymes with 
inflammation (in vitro) is consistent with lower levels of the metabolic products from 
these enzymatic reactions that we observed in older individuals with low SMI (in vivo, 
Figure 3).  
 
Limitations 
Because metabolites were measured in serum and not in the muscle, it is not 
possible to definitively distinguish muscle metabolic changes from metabolic changes 
that occur in other organ systems. However, measuring serum metabolites makes it 
possible to identify potential inter-organ cross-talk. In addition, the nature of 
metabolomics makes it difficult to establish causation. However, the corroborating 
results from the metabolomics and transcriptomics studies allow us to generate new 
hypotheses and directions for future research to understand metabolic changes in 
arginine and proline metabolism associated with sarcopenia. 
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Conclusions 
In conclusion, we determined that the Arginine and proline metabolism 
pathway was most strongly associated with skeletal muscle mass in older adults; 
several metabolites of arginine and proline metabolism were observed to be lower in 
individuals with lower muscle mass. Further, we identified differential gene 
expression of arginine and proline metabolic enzymes with inflammation, results that 
corroborated the metabolomics study and help explain the relationship between 
arginine and proline metabolism and SMI with aging. While future research is 
necessary to fully elucidate the relationship between arginine and proline metabolism 
and skeletal muscle mass with aging, the present findings suggest therapies to 
manipulate the availability of arginine may improve skeletal muscle health in adults 
with chronic inflammation.
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CHAPTER 3 
SUMMARY AND FUTURE DIRECTIONS 
Summary 
The aim of this study was to identify circulating factors that regulate skeletal 
muscle mass in older adults, in order to identify metabolic disturbances that are 
associated with age-related skeletal muscle atrophy (i.e. sarcopenia) with the goal to 
identify potential therapeutic targets to attenuate sarcopenia. 
We identified, using the serum of older adults, that the Arginine and Proline 
Metabolism pathway was the metabolic pathway most strongly associated with 
skeletal muscle index (SMI) and the pathway that had the greatest impact. SMI is 
positively correlated with circulating levels of creatinine, glutamate, pyrroline-5-
carboxylate, proline, 1-pyrroline-2-carboxylate, and L-4-hydroxy-glutamate 
semialdehyde, and negatively correlated with circulating creatine. Upon initial 
examination of the current literature, the relationship between arginine and SMI in 
older adults was unclear; however, we identified that disruption of arginine 
metabolism may be driven by inflammation: in clinical trials, supplements containing 
arginine improve skeletal muscle health, but only in populations suspected to have 
elevated inflammation [1-3].  
To investigate the relationship between inflammation and arginine in skeletal 
muscle, we measured gene expression in the skeletal muscle of younger and older 
adults. We hypothesized that older adults would have higher inflammatory signaling 
and altered expression of the cationic amino acid transporter CAT-2. Surprisingly, 
there were no differences between younger and older adults in inflammatory signaling 
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or in the gene expression of CAT-1 or CAT-2. We believe that because younger and 
older adults had similar levels of inflammation, they also had similar CAT-1 and CAT-
2 gene expression. 
We turned to a primary human muscle cell model where we could induce 
inflammation to determine the relationship between inflammation and arginine in 
vitro. Incubation in the inflammatory cytokine TNF-α for 48 hours increased the gene 
expression of CAT-2 11-fold in males and 23-fold in females, demonstrating a link 
between inflammation and arginine metabolism in human skeletal muscle cells. 
Additionally, we measured the expression of genes that regulate arginine metabolism 
in differentiated muscle cells (myotubes) from five young females. Inflammation 
decreased the expression of genes regulating the synthesis of polyamines, which are 
correlated with exercise in rat skeletal muscle [4] and regulate cell proliferation and 
differentiation [5]. Gene expression of ornithine decarboxylase 1, which increases 
myoblast proliferation and delays differentiation [6], and spermidine synthase was 
reduced. A reduction in spermine oxidase, the enzyme that breaks down spermine into 
spermidine, causes muscle atrophy in mice [7]. In addition, TNF-α changed the 
expression of genes that regulate proline and hydroxyproline production, including a 
decrease in pyrroline-5-carboxylate reductase 1, an increase in prolyl 4-hydroxylase 
subunit alpha 1, and a reduction in ornithine aminotransferase. Proline and 
hydroxyproline are the most common amino acid residues in collagen, which is 
important for wound healing. These inflammation-induced changes in gene expression 
suggest that arginine metabolism may regulate skeletal muscle mass in older adults 
through changes in the metabolism of polyamines and proline metabolism.  
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Future research 
Although we observed increases in the gene expression of CAT-2 in response 
to TNF-α treatment, we do not know if there is a concomitant increase in CAT-2 
protein, nor do we know if arginine transport into skeletal muscle is increased by 
inflammation. As a future direction, CAT-2 protein expression and arginine uptake 
need to be measured in human myotubes to confirm that inflammation increases 
arginine transport in skeletal muscle cells. 
Another question that warrants further investigation is how arginine is 
catabolized in inflamed human myotubes. Our research indicates that inflammation 
increases CAT-2 gene expression, likely increasing arginine influx into myotubes. At 
the same time, inflammation decreases the amount of arginine used for polyamine 
synthesis and proline synthesis. The cellular need for increasing arginine during the 
inflammatory state remains unclear. Arginase and inducible nitric oxide synthase 
(iNOS) are two important pathways for arginine catabolism; however, arginase and 
iNOS were not differentially expressed after 48 hours of inflammation. It is possible 
that arginase and iNOS gene expression does change, but this change is not apparent at 
the 48-hour time-point. Alternatively, arginase or iNOS activity may be increased by 
inflammation through post-translational modifications. In future research, I would 
propose to culture myotubes in media containing arginine comprised of stable, 
isotopically labeled carbon atoms. Metabolic products formed from labeled arginine 
will contain these labeled carbon atoms, making it possible to precisely measure these 
metabolic products using mass spectrometry. Consequently, it will be possible to 
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determine how inflammation changes the relative distribution of arginine metabolic 
products. 
Our research demonstrates that inflammation results in increased gene 
expression of CAT-2 and changes in arginine metabolism. However, it is unclear if the 
changes in arginine metabolism induced by TNF-α are mediated by CAT-2 and altered 
arginine supply, or by an independent inflammatory mechanism unrelated to arginine. 
To determine if manipulating the availability of arginine can improve skeletal muscle 
health, it is important to distinguish the effects of inflammation from the effects of 
changes in arginine transport. This question can be investigated by manipulating the 
expression of CAT-2. If knocking down CAT-2 prevents TNF-α from causing the 
changes in the gene expression that we observed, then the effects of TNF-α are 
mediated by CAT-2 and alterations in arginine concentration.  
Further research into the effects of inflammation on whole-body arginine 
metabolism is also needed to translate these results into effective therapies to preserve 
skeletal muscle mass. First-pass extraction of dietary arginine [8] and endogenous 
arginine synthesis [9] determine the amount of arginine in circulation, and therefore, 
the amount of arginine available to skeletal muscle. It is unknown how these processes 
are altered by factors such as systemic or local inflammation, or by age or sex. 
Studying these interactions will provide insight into the cross-talk that occurs between 
skeletal muscle and the rest of the body and to potential therapies to attenuate the age-
related loss of skeletal muscle mass. 
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In conclusion, we sought to understand the relationship between sarcopenia 
and whole-body metabolism, and determined that skeletal muscle mass in older adults 
was most strongly associated with the Arginine and proline metabolism pathway. 
Individuals with lower muscle mass had lower levels of several metabolites of 
arginine and proline metabolism. Suspecting that inflammation played a role in the 
relationship between arginine and proline metabolism and skeletal muscle mass in 
aging adults, we measured key arginine and proline metabolic enzymes. We observed 
differential gene expression of arginine and proline metabolic enzymes with 
inflammation, results that corroborated the metabolomics study and suggest that 
increased inflammation may alter the demand for arginine in muscle. While further 
research is needed to elucidate the relationship between arginine and proline 
metabolism and skeletal muscle mass with aging, these findings suggest that 
manipulation of the availability of arginine may be an effective therapy to improve 
skeletal muscle health in adults with chronic inflammation. 
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